Read More

Ampio Pharma Offers Regulatory Update, Says FDA Did Not Agree With Co.’s Proposed Changes To Its AP-013 Trial And, As Such, ‘it will be very difficult to salvage AP-013 itself as a pivotal trial’

Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other

AMPE